A Phase 3, Multicenter, Randomized, Controlled, Open-label Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)
Phase of Trial: Phase III
Latest Information Update: 14 Jan 2019
At a glance
- Drugs Bortezomib (Primary) ; Daratumumab; Melphalan; Prednisone
- Indications Multiple myeloma
- Focus Therapeutic Use
- Sponsors Janssen Research & Development
- 20 Dec 2017 Planned number of patients changed from 192 to 210.
- 20 Dec 2017 Status changed from not yet recruiting to recruiting.
- 15 Nov 2017 Planned End Date changed from 21 Oct 2022 to 31 Oct 2022.